Peninsula biotech sheds 90% of stock value after drug trials flop. By Ron Leuty – Senior Reporter, San Francisco Business Times. Dec 22, 2021.
News
- Allakos sheds 90% of stock value after drug trials flop - San Francisco Business Times
- Here's what you need to know about getting tested for COVID-19 in San Antonio - Texas Public Radio
Pfizer's antiviral pill Paxlovid to treat COVID-19 was authorized by the Food and Drug · Bioscience-Medicine · FDA authorizes 1st antiviral pill for ...
- FDA authorizes 1st antiviral pill for COVID | TPR - Texas Public Radio
Scott Hensley edits stories about health, biomedical research and ... what you need to know about getting tested for COVID-19 in San Antonio.
- Theranos' Elizabeth Holmes, Zymergen and Covid make 2021's top biotech-health stories
The good, the bad and the downright ugly of the year in biotech and health.
- Paychex, Tesla rise; CalAmp, Allakos fall - San Antonio Express-News
Investors were disappointed with the biotechnology company's latest update on its drug development program. CalAmp Corp., down $2.55 to $7.34.